![](https://ocpe.mcw.edu/sites/default/files/styles/course_image/public/The-Expanding-Role-of-Immunotherapy-in-Bladder-Cancer-Treatment-copy.png?itok=TbPHQr6w)
Webcast - Expanding Role of Immunotherapy in Bladder Cancer Treatment (IBCU2)
Welcome to the online CME program “The Expanding Role of Immunotherapy in Bladder Cancer Treatment”. To complete the activity, you will first need to do the pre-test and then watch and learn from two video lectures. Once this course is completed, you will be redirected to the Medical College of Wisconsin’s website to claim your CME for this activity.
Program Goal
The goal of this educational program is to equip urologists, medical oncologists, radiation oncologists, and other healthcare providers nationwide who are involved in the treatment of patients with bladder cancer with the upto-date clinical knowledge and tools they need to best diagnose and treat their patients. With growing advancements in immunotherapy treatment of bladder cancer, patients may experience better treatment outcomes.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Medical College of Wisconsin and Carden Jennings Publishing. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
The Medical College of Wisconsin designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Link to this activity: https://grandroundsinurology.com/courses/the-expanding-role-of-immunotherapy-in-bladder-cancer-treatment/
Target Audience
This activity has been developed and is intended for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the treatment of bladder cancer.
Learning Objectives
The following are the learning objectives in CME format for this program. Upon completion of
this program, participants will be able to effectively address:
- Recognize the role of the immune system in cancer development and resisting carcinogenesis
- Describe the mechanism of action of immunotherapy options compared to other therapeutic treatments in bladder cancer
- Assess clinical data on different immunotherapy options and their implications on therapy decision making in bladder cancer treatment
- Identify the emerging role of biomarkers for immunotherapy treatment in bladder cancer
1. Introcution/Pre-Test - Ashish M. Kamat, MD
2. The Expanding Role of Immunotheray in Bladder Cancer Treatment - Peter Black, MD
3. The Biomarkers in Immunotherapy for Bladder Cancer - Ashish M. Kamat, MD
4. Course Completion
PROGRAM CHAIR
E. David Crawford, MD, University of Colorado, Denver School of Medicine, Aurora, CO
Peter Black, MD, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada
Ashish M. Kamat, MD, MBBS, FACS, The University of Texas, MD Anderson Cancer Center, Houston, TX
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Medical College of Wisconsin and Carden Jennings Publishing. The Medical College of Wisconsin is accredited with commendation by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
MCW designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Available Credit
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.